{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:25:12Z","timestamp":1786940712586,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"DOI":"10.1186\/s12917-024-04340-0","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T04:03:23Z","timestamp":1729915403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis"],"prefix":"10.1186","volume":"20","author":[{"given":"Agnieszka","family":"Jasiecka-Miko\u0142ajczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Socha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"4340_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","volume":"37","author":"AJ Gonzales","year":"2014","unstructured":"Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37:317\u201324.","journal-title":"J Vet Pharmacol Ther"},{"key":"4340_CR2","doi-asserted-by":"publisher","first-page":"110537","DOI":"10.1016\/j.vetimm.2022.110537","volume":"256","author":"MM Aleo","year":"2023","unstructured":"Aleo MM, Messamore J, Nieto BA, Fleck TJ, Humphrey WR, Coscarelli EM, Mahabir SP, McCall RB, Gonzales AJ. Lack of interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs. Vet Immunol Immunopathol. 2023;256:110537.","journal-title":"Vet Immunol Immunopathol"},{"key":"4340_CR3","unstructured":"EMA\/436990\/2013. Available here: www.ema.europa.eu\/en\/documents\/overview\/apoquel-epar-summary-public_en.pdf"},{"key":"4340_CR4","unstructured":"US Food and Drug Administration. Apoquel. Oclacitinib Tablet. Freedom of information summary. Original new drug application. NADA 141\u2013345. Available here: www.animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/902"},{"key":"4340_CR5","unstructured":"Apoquel. Summary of product characteristics. Available from here: www.ec.europa.eu\/health\/documents\/community-register\/2013\/20130912126630\/anx_126630_en.pdf"},{"key":"4340_CR6","first-page":"204","volume":"57","author":"J Bajwa","year":"2016","unstructured":"Bajwa J. Canine superficial pyoderma and therapeutic considerations. Can Vet J. 2016;57:204\u20136.","journal-title":"Can Vet J"},{"key":"4340_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/vde.12118","volume":"25","author":"A Hillier","year":"2014","unstructured":"Hillier A, Lloyd DH, Weese JS, Blondeau JM, Boothe D, Breitschwerdt E, Guardabassi L, Papich MG, Rankin S, Turnidge JD, Sykes JE. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet Dermatol. 2014;25:163\u2013e43.","journal-title":"Vet Dermatol"},{"key":"4340_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.rvsc.2018.10.014","volume":"121","author":"A Jasiecka-Miko\u0142ajczyk","year":"2018","unstructured":"Jasiecka-Miko\u0142ajczyk A, Jaroszewski JJ, Ma\u015blanka T. Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro. Res Vet Sci. 2018;121:124\u20139.","journal-title":"Res Vet Sci"},{"key":"4340_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.24425\/pjvs.2023.145049","volume":"26","author":"A Jasiecka-Miko\u0142ajczyk","year":"2023","unstructured":"Jasiecka-Miko\u0142ajczyk A, Ma\u015blanka T. Depletion of T and B cells in lymphoid tissues of mice induced by oclacitinib, a Janus kinase inhibitor. Pol J Vet Sci. 2023;26:431\u201340.","journal-title":"Pol J Vet Sci"},{"key":"4340_CR10","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.3390\/molecules26185655","volume":"26","author":"A Jasiecka-Miko\u0142ajczyk","year":"2021","unstructured":"Jasiecka-Miko\u0142ajczyk A, Jaroszewski JJ, Ma\u015blanka T. Oclacitinib, a Janus Kinase Inhibitor, reduces the frequency of IL-4- and IL-10-, but not IFN-\u03b3-, producing murine CD4+ and CD8+ T cells and counteracts the Induction of Type 1 Regulatory T cells. Molecules. 2021;26:5655.","journal-title":"Molecules"},{"key":"4340_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fimmu.2015.00171","volume":"6","author":"G Churlaud","year":"2015","unstructured":"Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg M, Klatzmann D. Human and mouse CD8(+)CD25(+)FOXP3(+) Regulatory T cells at Steady State and during Interleukin-2 therapy. Front Immunol. 2015;6:171.","journal-title":"Front Immunol"},{"key":"4340_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13223-021-00577-8","volume":"17","author":"L Lin","year":"2021","unstructured":"Lin L, Dai F, Wei J, Chen Z. CD8+ tregs ameliorate inflammatory reactions in a murine model of allergic rhinitis. Allergy Asthma Clin Immunol. 2021;17:74.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"4340_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ni1179","volume":"6","author":"JD Fontenot","year":"2005","unstructured":"Fontenot JD, Rudensky AY. A well-adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6:331\u20137.","journal-title":"Nat Immunol"},{"key":"4340_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/eji.200737529","volume":"38","author":"M Mahic","year":"2008","unstructured":"Mahic M, Henjum K, Yaqub S, Bj\u00f8rnbeth BA, Torgersen KM, Task\u00e9n K, Aandahl EM. Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. Eur J Immunol. 2008;38:640\u20136.","journal-title":"Eur J Immunol"},{"key":"4340_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12915-022-01502-0","volume":"21","author":"S M\u00e9noret","year":"2023","unstructured":"M\u00e9noret S, Tesson L, Remy S, Gourain V, S\u00e9razin C, Usal C, Guiffes A, Chenouard V, Ouisse LH, Gantier M, Heslan JM, Fourgeux C, Poschmann J, Guillonneau C, Anegon I. CD4+ and CD8+ regulatory T cell characterization in the rat using a unique transgenic Foxp3-EGFP model. BMC Biol. 2023;21:8.","journal-title":"BMC Biol"},{"key":"4340_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50:302\u201316.","journal-title":"Immunity"},{"key":"4340_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.vetimm.2008.02.008","volume":"123","author":"KE Keppel","year":"2008","unstructured":"Keppel KE, Campbell KL, Zuckermann FA, Greeley EA, Schaeffer DJ, Husmann RJ. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy. Vet Immunol Immunopathol. 2008;123:337\u201344.","journal-title":"Vet Immunol Immunopathol"},{"key":"4340_CR18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/vde.12140","volume":"25","author":"J-VD Lee","year":"2014","unstructured":"Lee J-VD, Rutten A, Bruijn VP, Willemse J, Broere T. CD4\u2060+ and CD8\u2060+ skin-associated T lymphocytes in canine atopic dermatitis produce interleukin-13, interleukin-22 and interferon-\u03b3 and contain a CD25\u2060+ FoxP3\u2060+ subset. Vet Dermatol. 2014;25:456\u2013e72.","journal-title":"Vet Dermatol"},{"key":"4340_CR19","doi-asserted-by":"publisher","first-page":"e0153682","DOI":"10.1371\/journal.pone.0153682","volume":"11","author":"JD Goldstein","year":"2016","unstructured":"Goldstein JD, Burlion A, Zaragoza B, Sendeyo K, Polansky JK, Huehn J, Piaggio E, Salomon BL, Marodon G. Inhibition of the JAK\/STAT Signaling Pathway in Regulatory T Cells reveals a very dynamic regulation of Foxp3 expression. PLoS ONE. 2016;11:e0153682.","journal-title":"PLoS ONE"},{"key":"4340_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/vde.13037","volume":"33","author":"G De Caro Martins","year":"2022","unstructured":"De Caro Martins G, da Costa-Val AP, Coura FM, Diamantino GML, Nogueira MM, de Melo-Junior O. Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis. Vet Dermatol. 2022;33:142\u2013e40.","journal-title":"Vet Dermatol"},{"key":"4340_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.vetimm.2012.06.003","volume":"149","author":"DA Plager","year":"2012","unstructured":"Plager DA, Torres SMF, Koch SN, Kita H. Gene transcription abnormalities in canine atopic dermatitis and related human eosinophilic allergic diseases. Vet Immunol Immunopathol. 2012;149:136\u201342.","journal-title":"Vet Immunol Immunopathol"},{"key":"4340_CR22","doi-asserted-by":"crossref","unstructured":"Ramirez GA, Yacoub MR, Ripa M, Mannina D, Cariddi A, Saporiti N, Ciceri F, Castagna A, Colombo G, Dagna L. Eosinophils from physiology to Disease: a Comprehensive Review. Biomed Res Int. 2018;9095275.","DOI":"10.1155\/2018\/9095275"},{"key":"4340_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.rvsc.2012.01.018","volume":"93","author":"T Ma\u015blanka","year":"2012","unstructured":"Ma\u015blanka T, Jaroszewski JJ. In Vitro effects of dexamethasone on bovine CD25+CD4+ and CD25-CD4+ cells. Res Vet Sci. 2012;93:1367\u201379.","journal-title":"Res Vet Sci"},{"key":"4340_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38:13\u201325.","journal-title":"Immunity"},{"key":"4340_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1365-2133.1992.tb00119.x","volume":"127","author":"JM Sowden","year":"1992","unstructured":"Sowden JM, Powell RJ, Allen BR. Selective activation of circulating CD4+ lymphocytes in severe adult atopic dermatitis. Br J Dermatol. 1992;127:228\u201332.","journal-title":"Br J Dermatol"},{"key":"4340_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2222.1993.tb00310.x","volume":"23","author":"C Walker","year":"1993","unstructured":"Walker C, K\u00e4gi MK, Ingold P, Braun P, Blaser K, Bruijnzeel-Koomen CA, W\u00fcthrich B. Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity. Clin Exp Allergy. 1993;23:145\u201353.","journal-title":"Clin Exp Allergy"},{"key":"4340_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/vaccines10071037","volume":"10","author":"A Majewska","year":"2022","unstructured":"Majewska A, Dembele K, Dziendzikowska K, Prostek A, Gajewska M. Cytokine and lymphocyte profiles in dogs with atopic dermatitis after Allergen-Specific Immunotherapy. Vaccines. 2022;10:1037.","journal-title":"Vaccines"},{"key":"4340_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12917-016-0805-6","volume":"12","author":"A Majewska","year":"2016","unstructured":"Majewska A, Gajewska M, Dembele K, Maciejewski H, Prostek A, Jank M. Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis. BMC Vet Res. 2016;12:174.","journal-title":"BMC Vet Res"},{"key":"4340_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","volume":"490","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174\u201385.","journal-title":"Cancer Lett"},{"key":"4340_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-3164.2009.00758.x","volume":"21","author":"C Favrot","year":"2010","unstructured":"Favrot C, Steffan J, Seewald W, Picco F. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol. 2010;21:23\u201331.","journal-title":"Vet Dermatol"},{"key":"4340_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.rvsc.2012.12.005","volume":"94","author":"T Ma\u015blanka","year":"2013","unstructured":"Ma\u015blanka T, Jaroszewski JJ, Markiewicz W, Jasiecka A, Zi\u00f3\u0142kowski H, J\u0119drzkiewicz D. Effects of dexamethasone and meloxicam on bovine CD25+ CD8+ and CD25- CD8+ T cells-in vitro study. Res Vet Sci. 2013;94:662\u201374.","journal-title":"Res Vet Sci"},{"key":"4340_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jvp.12087","volume":"37","author":"WT Collard","year":"2014","unstructured":"Collard WT, Hummel BD, Fielder AF, King VL, Boucher JF, Mullins MA, Malpas PB, Stegemann MR. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J Vet Pharmacol Ther. 2014;37:279\u201385.","journal-title":"J Vet Pharmacol Ther"},{"key":"4340_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.rvsc.2020.05.011","volume":"132","author":"A Jasiecka-Miko\u0142ajczyk","year":"2020","unstructured":"Jasiecka-Miko\u0142ajczyk A, Socha P. Teriflunomide inhibits activation-induced CD25 expression on T cells and may affect Foxp3-expressing regulatory T cells. Res Vet Sci. 2020;132:17\u201327.","journal-title":"Res Vet Sci"},{"key":"4340_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.vetimm.2006.12.002","volume":"116","author":"BJ Biller","year":"2007","unstructured":"Biller BJ, Elmslie RE, Burnett RC, Avery AC, Dow SW. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol. 2007;116:69\u201378.","journal-title":"Vet Immunol Immunopathol"},{"key":"4340_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u20136.","journal-title":"Nat Immunol"},{"key":"4340_CR36","doi-asserted-by":"publisher","first-page":"7259","DOI":"10.4049\/jimmunol.173.12.7259","volume":"173","author":"MA Curotto de Lafaille","year":"2004","unstructured":"Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol. 2004;173:7259\u201368.","journal-title":"J Immunol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-024-04340-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-024-04340-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-024-04340-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T16:02:07Z","timestamp":1729958527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-024-04340-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4340"],"URL":"https:\/\/doi.org\/10.1186\/s12917-024-04340-0","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Only stored samples have been used in this study. The blood was not sampled for the purpose of the study described in this paper. The dogs involved were not submitted to any procedure in order to obtain the results discussed in this article. All participating dogs were regular patients of the Small Animal Veterinary Clinic in Biskupiec (Poland). PB samples were collected for regular monitoring of complete blood count on request by the attending veterinary doctor. Owing to the kind cooperation of the dogs\u2019 owners and veterinary doctors, the unused blood from laboratory tests was made available for the present study. In each case, the owners informed consent to the use of blood of their dogs for scientific research has been obtained. The acquisition of biological material for research under the circumstances as described above does not require an approval of the Ethics Commission in Poland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"489"}}